{"paper_id":"a29af04a-0579-4a5f-bcab-b9c4122006b0","body_text":"~ 13 ~ \nInternational Journal of Clinical Obstetrics and Gynaecology 2018; 2(3): 13-15 \n \nISSN (P): 2522-6614 \nISSN (E): 2522-6622 \n© Gynaecology Journal \nwww.gynaecologyjournal.com \n2018; 2(3): 13-15 \nReceived: 04-03-2018 \nAccepted: 05-04-2018 \n \nDr. Anima Prasad \nProfessor & HOD, Hind Institute \nof Medical Sciences, Ataria, \nSitapur, Uttar Pradesh, India \n \nDr. Amrish Kumar \nConsultant Pathologist, Dr. \nShyama Prasad Mukherjee (Civil) \nHospital, Lucknow, Uttar Pradesh, \nIndia \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nCorrespondence \nDr. Anima Prasad \nProfessor & HOD, Hind Institute \nof Medical Sciences, Ataria, \nSitapur, Uttar Pradesh, India \n \nAssessment of cases of endometrial hyperplasia in \nfemales \n \nDr. Anima Prasad and Dr. Amrish Kumar \n \nAbstract \nBackground: Endometrium is capable of marked hyperplasia as a response to stimulus of prolonged and \nunopposed oestrogen. The present study was conducted to assess endometrial hyperplasia in females. \nMaterials & Methods: The present study was conducted on 45 females with history of menorrhagia. \nGeneral information such as name, age, drug history of estrogen etc. was recor ded. Per rectum examination \nwas done in all patients. In all patients, transvaginal ultrasound (TVS) was doneto seeendometrial thickness \nand ovarian enlargement. After curettage, histopathology of the specimens was done. \nResults: Age group 40-45 years had 22 patients, 45-50 had 14, 50-55 had 8 and 55-60 years had 6 patients. \nThe difference was significant (P - 0.01). Type of hyperplasia was cystic hyperplasia (28), adenomatous \nhyperplasia (10) and atypical hyperplasia (7). The difference was significant (P - 0.05). Endometrial \nthickness on transvaginal ultrasound (TVS) was 5 -6 mm seen in 7 cases, 7 -8 mm seen in 12 cases and >10 \nmm seen in 26 cases. The difference was significant (P<0.05). \nConclusion: Author concluded that endometrial hyperplasia was most commo nly seen in age group 40- 45 \nyears. Most common type of hyperplasia was cystic hyperplasia. \n \nKeywords: Cystic hyperplasia, endometrial hyperplasia, transvaginal ultrasound \n \nIntroduction  \nEndometrium is capable of marked hyperplasia as a  response to stimulu s of prolonged and \nunopposed oestrogen. Of the  two systems used to classify EH, namely, the World Health \nOrganization (WHO) and the endometrial intraepithelial neoplasia (EIN) classification systems,  \nthe EIN system is more objective than the WHO system, but the latter is more widely used [1]. \nSimple or cystic hyperplasia is a benign proliferation of endometrial glands that are irregular and \ndilated but do  not display back to back crowding or cellular atypia.  Complex adenomatous  \nhyperplasia is a proliferatio n of  endometrial glands with irregular outline architectural  \ncomplexity and back to back crowding but no atypia [2]. \nThe endometrioid  adenocarcinoma is the most  frequent histologic variant, accounting for 58 -\n80% of the cases. Almost all cases of that histo logic type are hormone-dependent and associated \nwith obesity, exogeneous use of hormones, and elevated estrogen levels. The lesion is known to \narise from an endometrial hyperplasia. The risk of progression of  hyperplasia into endometrioid \ncarcinoma is more  closely related to the presence of cytologicatypia and  to architectural \ncrowding [3]. \nEpplein et al . [4] in their study of risk of complex  and atypical endometrial hyperplasia in \nrelation to anthropometric measures and reproductive history found that estr ogen-only hormone \ntherapy, which is a type  of menopausal hormone therapy (MHT), is a risk factor for EH. \nArmstrong et al. [5] conducted a study of diagnosis and  management of endometrial hyperplasia \nsuggested that hormonal therapy is the major risk factor in women leading to endometrial \nhyperplasia. The present study was conducted to assess endometrial hyperplasia in females. \n \nMaterials & Methods \nThe present study was conducted in the department of Gynecology & Obstetrics. It comprised of \n45 females with hi story of menorrhagia. All were informed regarding the study and written \nconsent was obtained. Ethical clearance was taken before starting the study from the institutional \nethical committee. \nGeneral information such as name, age, drug history of estrogen et c. was recorded. All were \nsubjected to general physical  and pelvic examination. Per rectum  examination was done in all \npatients. Routine investigations such as blood group, Rh-factor, random blood sugar and urine \n\n\nInternational Journal of Clinical Obstetrics and Gynaecology \n~ 14 ~ \nroutine was performed. In all patients, t rans vaginal ultrasound \n(TVS) was done  to see for endometrial thickness and ovarian  \nenlargement. Curettage and histopathology of the specimens was \ndone. Results thus obtained were subjected to statistical analysis \nusing chi - square test. P value less than 0.05 was considered \nsignificant. \n \nResults \n \nTable I: Age wise distribution of cases \n \nAge group (years) Number P value \n40-45 22 \n0.01 45-50 14 \n50-55 8 \n55-60 6 \n \nTable I shows that age group 40 -45 years had 22 patients, 45 -50 \nhad 14, 50 -55 had 8 and 55 -60 years had 6 patients. The \ndifference was significant (P- 0.01). \n \nTable II: Type of endometrial hyperplasia \n \nType Number P value \nCystic hyperplasia 28 \n0.05 Adenomatous hyperplasia 10 \nAtypical hyperplasia 7 \nTotal 45 \n \nTable II shows that type of hy perplasia was cystic hyperplasia \n(28), adenomatous hyperplasia (10) and atypical hyperplasia (7). \nThe difference was significant (P- 0.05). \n \n \n \nGraph I: Endometrial thickness on transvaginal ultrasound (TVS) \n \nGraph I shows that endometrial thickness on tra nsvaginal \nultrasound (TVS) was 5 -6 mm seen in 7 cases, 7 -8 mm seen in \n12 cases and >10 mm seen in 26 cases. The difference was \nsignificant (P<0.05). \n \nDiscussion \nEndometrial hyperplasia is a precursor of endometrial \ncarcinoma. It accounts for 6% of new  female cases and 3% of \nfemale cancer deaths. It is the most common malignancy  of \nfemale reproductive tract. Studies have revealed that  \noestrogentherapy, obesity, diabetes early menarche and late  \nmenopause are amongst various risk factors for endometrial \nhyperplasia. The risk of progression of  hyperplasia into \nendometrial carcinoma is more closely related to the presence of \ncytologic atypia and to architectural crowding. The morphologic \ndistinction between atypical hyperplasia and well -differentiated \ncarcinoma i n an endometrial biopsy or in curetting may be \nproblematic with a marked variation of  inter-observer \ncorrelation [6]. \nIn present study, 45 females were found to have endometrial \nhyperplasia. We found that age group 40 -45 years had 22 \npatients, 45 -50 had 14 , 50 -55 had 8 and 55 -60 years had 6 \npatients. This is in agreement with Tavasoli et al. [7] \nThe simple cystic hyperplasia is a benign proliferation with the \nreported risk 0 -1% of progression into carcinoma. In this study, \ntype of hyperplasia was cystic hyp erplasia (28), adenomatous \nhyperplasia (10) and atypical hyperplasia (7). Amera et al. [8] in \ntheir study found that out of 100 patients, 15patients were found \nto have endometrial hyperplasia, 10 patients simple cystic \nhyperplasia, 3patients had adenomotou s hyperplasia, 2 patients \nhad atypical hyperplasia, 8 patients had menorrhagia , 1 with \npolymenorrhagia, and 6 patients with  polymenorrhoea. 13 \npatients were  treated medically, 5 patients needed surgical \ntreatment following medical treatment, 2  patients und erwent \ntotal abdominal hysterectomy (TAH) and bilateral \nsalpingooophorectomy (BSO) who were 51 –53 years of age \nwith atypical hyperplasia. Author suggested that endometrial \nhyperplasia is a pre -malignant condition; if treated in time, \nincidence can be reduc ed and  early treatment can increase life \nexpectancy and quality in women over age of 45 years. \nHorn et al . [9] found that 86% of the patients presented with \nobesity, 23% had an exogeneous use of  estrogens. The leading \nsymptom was vaginal bleeding in 65.5% of patients. 91% had \ncomplex, 92% had atypical hyperplasia and 89% had \nendometrioidcarcinoma, representing an overall correlation of \n90%. 2% of the cases with complex hyperplasia progressed into \ncarcinoma and  10.5% into atypical hyperplasia. 52% of the \natypicalhyperplasias progressed into carcinomas. In the case of \nprogestogen treatment, 61.5% showed remission confirmed  by \nre-curetting, compared with 20.3% of the cases without \nhormonal treatment. \nWe subjected patients to TVS and found that endometrial \nthickness was 5-6 mm seen in 7 cases, 7 -8 mm seen in 12 cases \nand >10 mm seen in 26 cases. This is similar to Campbel  et al. \n[10] Jin [11] in her study included 1,868 women with EH and 868 \nwomen with EC. The mean ages of the patients were 44.1 - 0.4 \nyears for th ose with EH and 52.7 - 0.6 years for those with EC. \nThe EH and EC incidence rates were 3.7%woman -years and 8% \nwoman-years, respectively. The EH and EC incidence  rates \npeaked when the women were in their late forties and fifties, \nrespectively. \nIn a study by  Terakawa et al. [12], 51 patients with endometrial  \nhyperplasia were followed for 6 months, with repeated  \nendometrial biopsy monthly for 3 months and at the end  of 6 \nmonths. In 69% histology became normal. Jalil R  [13] correlated \nthe indications of abdominal hysterectomy with histopahological \nfindings in her reports preoperative  diagnosis, by D&C of \nendometrial hyperplasia was14.42%. \nIn the study of  Ferenczy and Gelfand  [14] it is stated that 10 out \nof 20  patients treated with progestogens for ‘endometrial  \nhyperplasia with cytologicatypia’ had a persistence  and five of \nthem recurred. Additionally, five patients  developed an \nadenocarcinoma during a mean follow  uptime 5.5 years. \nProgestogens are the treatment of choice of endometrial  \nhyperplasia because of their i nhibitory effect on epithelial \nproliferation. They act by reducing estrogenic  receptors and \nincreasing their catabolism,  stimulating the 17 -b-\nhydroxyesteroid dehydrogenase  and sulfotransferase enzymes \nand thereby diminishing the estrogenic dominant conditions that \nlead to endometrial abnormalities which occur in \nhyperestrogenism. \n\nInternational Journal of Clinical Obstetrics and Gynaecology \n~ 15 ~ \nConclusion \nAuthor concluded that endometrial hyperplasia was most \ncommonly seen in age group 40 - 45 years. Most common type \nof hyperplasia was cystic hyperplasia.  \n \nReferences \n1. Kurman RJ, Kamiriski PF, Norris HJ. The behavior of \nendometrial hyperplasia; A long term study of untreated \nendometrial hyperplasia in 170 patients. Cancer . 1985; \n56:403-12. \n2. Wentz WB. Progestin therapy in endometrial hyperplasia. \nGynaecol Oncol. 1974; 2:362-7. \n3. Mishal DR, Droegmuller -W, Merbot -AL. Abdominal \nuterine bleeding. Corhensive Gynaecology, 2011, 953-64. \n4. Fayyaz S, Majeed SS. Audit of Gynaecological  \nhysterectomies. J Postgrad Med Inst. 2001; 15(2):208–12. \n5. Terakawa N, Kigawa J, Taketani Y, Yoshikawa H, Yajima  \nA, Noda K et al. The behavior of endometrial hyperplasia: \naprospective study. J  Obstet Gynaecol Res . 1997; \n23(3):223-30. \n6. Menwissen JH et al. Endometrial Biopsy the female  patient \n1993; 4:19–23. \n7. Tavasoli, Ben Yehuda OM, Kim YB, Leuchter RS. Does \nHysteroscopy improve upon the sensitivity of dilatation and \ncurettage in the  diagnosis of endometrial hyperplasia or \ncarcinoma? Gynaecol Oncol 1998; 68(1):4-7. \n8. Amera, Tan KT, Pang MW.  Ho TH. Endometrial \nhyperplasia and the risk of endometrial carcinoma. \nSingapore Med J. 1997; 38(1):11–5. \n9. Horn, Reich O, Tamussino K, Bader AA, Pieber D, Schöll \nW et al. Concomitant endometrial Hyperplasia in patients \nwith endometrial carcinoma. Gynaecol  Oncol. 1998; \n69(1):64-8. \n10. Campbel, Colacurci N, De Placido G, Mollo A, Perino A, \nCittadini E.  Short term use of Goserlin Depot in the \ntreatment ofdys functional uterine bleeding. Clin Exp Obstet \nGynecol. 1995; 22:212-9. \n11. Jin RJ. Not so benign endometrial hyperplasia: endometrial \ncancer after endometrial ablation. J Am Assoc Gynaecol  \nLaprarosc. 1997; 4(4):507-11. \n12. Terakawa, Kaku T, Tsukamoto N, Hachisuga T et al . \nEndometrial carcinoma associated with hyperplasia. \nGynecol Oncol. 1996; 60:22-5. \n13. Jalil, Skov BG, Broholm H, Engel U et al. Comparison of \nthere producibility of the WHO classifications of 19 75 and \n1994 of endometrial hyperplasia. Int J Gynecol  Pathol. \n1997; 16:33-7. \n14. Ferenczy and Gelfand. Endometrioidneoplasia retrogressive \nterminology. AmJ Surg Pathol. 2000; 24:754-5.","source_license":"CC0","license_restricted":false}